RxDoctor Payments Data

Deborah Gunden, NP

Adult Health · Goshen, INNPI 1376514380

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 34.5% of the total. Reporting peaked in 2023 at $1,467 and has fallen 64.6% since, to $520 in 2025. Among adult health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,756in general payments, 2019–2025

Across 291 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$873
  • Takeda Pharmaceuticals U.S.A., Inc.$535
  • Regeneron Healthcare Solutions, Inc.$246
  • Nestle Healthcare Nutrition Inc.$200
  • Phathom Pharmaceuticals, Inc.$156
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,68098%
  • Education$762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,756 in reported general payments places this provider in the 90th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$58,648
Medicare patients
391
Services billed
1,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase11$51,895
LinzessLinaclotide43$34,806
Pantoprazole Sodium525$6,201
Famotidine336$5,328
Dicyclomine Hcl90$2,131
Omeprazole138$2,098
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine44$1,819
Ondansetron OdtOndansetron42$1,477
Esomeprazole Magnesium40$1,452
Ondansetron Hcl29$430
LoperamideLoperamide Hcl13$268
Propranolol Hcl16$159
Imipramine Hcl12$144
Promethazine Hcl11$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,640$86,70254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 adult health providers in Indiana.

Other adult health in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →